{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:22:29Z","timestamp":1790904149912,"version":"4.1.0"},"reference-count":113,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Foundation Pediatric Oncology Center Rotterdam"},{"DOI":"10.13039\/501100006244","name":"KiKa","doi-asserted-by":"crossref","award":["132"],"award-info":[{"award-number":["132"]}],"id":[{"id":"10.13039\/501100006244","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ejca.2017.06.012","type":"journal-article","created":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T06:31:35Z","timestamp":1499841095000},"page":"203-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["BCR-ABL1 -like acute lymphoblastic leukaemia: From bench to bedside"],"prefix":"10.1016","volume":"82","author":[{"given":"Judith M.","family":"Boer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique L.","family":"den Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejca.2017.06.012_bib1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1200\/JCO.2010.30.7405","article-title":"Biology, risk stratification, and therapy of pediatric acute leukemias: an update","volume":"29","author":"Pui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2017.06.012_bib2","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1200\/JCO.2015.64.6364","article-title":"Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: study ALL10 from the Dutch Childhood Oncology Group","volume":"34","author":"Pieters","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2017.06.012_bib3","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(12)70377-7","article-title":"Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study","volume":"13","author":"Biondi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.06.012_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","article-title":"A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study","volume":"10","author":"Den Boer","year":"2009","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2017.06.012_bib5","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1056\/NEJMoa0808253","article-title":"Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia","volume":"360","author":"Mullighan","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.06.012_bib6","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1038\/bcj.2016.28","article-title":"Characterization of pediatric philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan","volume":"6","author":"Imamura","year":"2016","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.ejca.2017.06.012_bib7","doi-asserted-by":"crossref","first-page":"e261","DOI":"10.3324\/haematol.2014.117424","article-title":"Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates","volume":"100","author":"Boer","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ejca.2017.06.012_bib8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3324\/haematol.2015.136366","article-title":"Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis","volume":"102","author":"Herold","year":"2017","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.ejca.2017.06.012_bib9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/leu.2016.375","article-title":"High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL","volume":"31","author":"Tasian","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.ejca.2017.06.012_bib10","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejca.2017.06.012_bib11","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults","volume":"35","author":"Roberts","year":"2017","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2017.06.012_bib12","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2017.06.012_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/MOH.0000000000000050","article-title":"Beyond Philadelphia: \u2018Ph-like\u2019 B cell precursor acute lymphoblastic leukemias \u2013 diagnostic challenges and therapeutic promises","volume":"21","author":"Izraeli","year":"2014","journal-title":"Curr Opin Hematol"},{"issue":"11","key":"10.1016\/j.ejca.2017.06.012_bib14","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.3324\/haematol.2013.095372","article-title":"Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion","volume":"98","author":"Lengline","year":"2013","journal-title":"Haematologica"},{"issue":"25","key":"10.1016\/j.ejca.2017.06.012_bib15","doi-asserted-by":"crossref","first-page":"e413","DOI":"10.1200\/JCO.2012.47.6770","article-title":"Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia","volume":"31","author":"Weston","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2017.06.012_bib16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","article-title":"Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia","volume":"22","author":"Roberts","year":"2012","journal-title":"Cancer Cell"},{"issue":"22","key":"10.1016\/j.ejca.2017.06.012_bib17","first-page":"583","article-title":"JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia","volume":"128","author":"Steeghs","year":"2016","journal-title":"Annu Meet Abstr Blood"},{"issue":"15","key":"10.1016\/j.ejca.2017.06.012_bib18","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1182\/blood-2012-10-462358","article-title":"Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL","volume":"122","author":"Van der Veer","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ejca.2017.06.012_bib19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood-2012-04-422691","article-title":"Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET project","volume":"121","author":"Loh","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ejca.2017.06.012_bib20","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.3324\/haematol.2015.124941","article-title":"BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG\/Erasmus MC and COG\/St. Jude signatures","volume":"100","author":"Boer","year":"2015","journal-title":"Haematologica"},{"issue":"26","key":"10.1016\/j.ejca.2017.06.012_bib21","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","article-title":"Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic\/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia","volume":"115","author":"Harvey","year":"2010","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.ejca.2017.06.012_bib22","first-page":"3735","article-title":"Clinical relevance of tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia","volume":"126","author":"Boer","year":"2015","journal-title":"Annu Meet Abstr Blood"},{"issue":"21","key":"10.1016\/j.ejca.2017.06.012_bib23","first-page":"826","volume":"122","author":"Harvey","year":"2013","journal-title":"Annu Meet Abstr Blood"},{"issue":"6","key":"10.1016\/j.ejca.2017.06.012_bib24","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/sj.leu.2405033","article-title":"Fusion of ZMIZ1 to ABL1 in a B-cell acute lymphoblastic leukaemia with a t(9;10)(q34;q22.3) translocation","volume":"22","author":"Soler","year":"2008","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.ejca.2017.06.012_bib25","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/sj.leu.2404773","article-title":"A new partner gene fused to ABL1 in a t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia","volume":"21","author":"De Braekeleer","year":"2007","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.ejca.2017.06.012_bib26","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/gcc.20796","article-title":"Acute leukemias with ETV6\/ABL1 (TEL\/ABL) fusion: poor prognosis and prenatal origin","volume":"49","author":"Zuna","year":"2010","journal-title":"Genes Chromosom Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2017.06.012_bib27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1365-2141.2010.08457.x","article-title":"Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia","volume":"153","author":"Ernst","year":"2011","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.ejca.2017.06.012_bib28","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/gcc.20585","article-title":"Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia","volume":"47","author":"Poitras","year":"2008","journal-title":"Genes Chromosom Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2017.06.012_bib29","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.18632\/oncotarget.13492","article-title":"Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia","volume":"8","author":"Boer","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.ejca.2017.06.012_bib30","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1182\/blood-2014-04-570960","article-title":"The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia","volume":"125","author":"Schinnerl","year":"2015","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.ejca.2017.06.012_bib31","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood-2009-03-208397","article-title":"Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia","volume":"114","author":"Russell","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ejca.2017.06.012_bib32","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ng.469","article-title":"Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia","volume":"41","author":"Mullighan","year":"2009","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.ejca.2017.06.012_bib33","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1073\/pnas.0911726107","article-title":"Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia","volume":"107","author":"Yoda","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.ejca.2017.06.012_bib34","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/gcc.22439","article-title":"Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia","volume":"56","author":"Russell","year":"2017","journal-title":"Genes Chromosom Cancer"},{"issue":"26","key":"10.1016\/j.ejca.2017.06.012_bib35","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1182\/blood-2012-07-443218","article-title":"Small sizes and indolent evolutionary dynamics challenge the potential role of P2RY8-CRLF2-harboring clones as main relapse-driving force in childhood ALL","volume":"120","author":"Morak","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejca.2017.06.012_bib36","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2011-12-389932","article-title":"Aberrant STAT5 and PI3K\/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia","volume":"120","author":"Tasian","year":"2012","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.ejca.2017.06.012_bib37","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1182\/blood-2011-11-394221","article-title":"Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"119","author":"Chen","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.06.012_bib38","doi-asserted-by":"crossref","first-page":"6604","DOI":"10.1038\/ncomms7604","article-title":"Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia","volume":"6","author":"Ma","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2017.06.012_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2016.365","article-title":"Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia","author":"Vesely","year":"2017","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.ejca.2017.06.012_bib40","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1073\/pnas.0811761106","article-title":"JAK mutations in high-risk childhood acute lymphoblastic leukemia","volume":"106","author":"Mullighan","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.ejca.2017.06.012_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/ng.924","article-title":"Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia","volume":"43","author":"Zenatti","year":"2011","journal-title":"Nat Genet"},{"issue":"5","key":"10.1016\/j.ejca.2017.06.012_bib42","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1084\/jem.20110580","article-title":"Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias","volume":"208","author":"Shochat","year":"2011","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.ejca.2017.06.012_bib43","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1182\/blood-2013-10-529685","article-title":"Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia","volume":"124","author":"Shochat","year":"2014","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.ejca.2017.06.012_bib44","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1182\/blood-2013-05-500850","article-title":"Genetic loss of SH2B3 in acute lymphoblastic leukemia","volume":"122","author":"Perez-Garcia","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ejca.2017.06.012_bib45","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/leu.2008.250","article-title":"A novel translocation, t(14;19)(q32;p13), involving IGH@ and the cytokine receptor for erythropoietin","volume":"23","author":"Russell","year":"2009","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ejca.2017.06.012_bib46","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ccell.2015.12.013","article-title":"Truncating erythropoietin receptor rearrangements in acute lymphoblastic leukemia","volume":"29","author":"Iacobucci","year":"2016","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.ejca.2017.06.012_bib47","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3324\/haematol.2016.144345","article-title":"Characterization of leukemias with ETV6-ABL1 fusion","volume":"101","author":"Zaliova","year":"2016","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.ejca.2017.06.012_bib48","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2016-05-707653","article-title":"Potent efficacy of combined PI3K\/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"129","author":"Tasian","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.06.012_bib49","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","article-title":"BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros","volume":"453","author":"Mullighan","year":"2008","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ejca.2017.06.012_bib50","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2008-08-173963","volume":"114","author":"Iacobucci","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ejca.2017.06.012_bib51","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2013-06-509794","article-title":"IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL","volume":"123","author":"van der Veer","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2017.06.012_bib52","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/leu.2015.199","article-title":"Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study","volume":"30","author":"Boer","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.ejca.2017.06.012_bib53","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/leu.2010.87","article-title":"IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL","volume":"24","author":"Kuiper","year":"2010","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.ejca.2017.06.012_bib54","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1084\/jem.20090004","article-title":"Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function","volume":"206","author":"Trageser","year":"2009","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.ejca.2017.06.012_bib55","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2010.63","article-title":"Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia","volume":"24","author":"Virely","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.ejca.2017.06.012_bib56","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1084\/jem.20160048","article-title":"Conserved IKAROS-regulated genes associated with B-progenitor acute lymphoblastic leukemia outcome","volume":"214","author":"Witkowski","year":"2017","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.ejca.2017.06.012_bib57","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ccell.2015.07.016","article-title":"Efficacy of retinoids in IKZF1-mutated BCR-ABL1 acute lymphoblastic leukemia","volume":"28","author":"Churchman","year":"2015","journal-title":"Cancer Cell"},{"issue":"15","key":"10.1016\/j.ejca.2017.06.012_bib58","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2015-06-651505","article-title":"Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia","volume":"126","author":"Song","year":"2015","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.ejca.2017.06.012_bib59","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2014.55.4105","article-title":"Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease","volume":"32","author":"Roberts","year":"2014","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2017.06.012_bib60","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1182\/blood-2015-09-670166","article-title":"EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications","volume":"127","author":"Schwab","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ejca.2017.06.012_bib61","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3563","article-title":"Role of ABL family kinases in cancer: from leukaemia to solid tumours","volume":"13","author":"Greuber","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"10.1016\/j.ejca.2017.06.012_bib62","first-page":"786","article-title":"Functional analysis of kinase-activating fusions in Ph-like acute lymphoblastic leukemia","volume":"124","author":"Roberts","year":"2014","journal-title":"Annu Meet Abstr Blood"},{"issue":"17","key":"10.1016\/j.ejca.2017.06.012_bib63","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1182\/blood-2012-03-415448","article-title":"Targeting JAK1\/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia","volume":"120","author":"Maude","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejca.2017.06.012_bib64","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1158\/1535-7163.MCT-14-0647","article-title":"Evaluation of the in\u00a0vitro and in\u00a0vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia","volume":"14","author":"Suryani","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.ejca.2017.06.012_bib65","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3324\/haematol.2015.125336","article-title":"A novel xenograft model to study the role of TSLP-induced CRLF2 signals in normal and malignant human B lymphopoiesis","volume":"101","author":"Francis","year":"2016","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.ejca.2017.06.012_bib66","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/ejh.12234","article-title":"Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript","volume":"92","author":"Masuzawa","year":"2014","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.ejca.2017.06.012_bib67","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.leukres.2013.11.017","article-title":"Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1","volume":"38","author":"Tomita","year":"2014","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.ejca.2017.06.012_bib68","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12185-011-0910-z","article-title":"RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations","volume":"94","author":"Inokuchi","year":"2011","journal-title":"Int J Hematol"},{"issue":"5","key":"10.1016\/j.ejca.2017.06.012_bib69","doi-asserted-by":"crossref","first-page":"e26328","DOI":"10.1002\/pbc.26328","article-title":"Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia","volume":"64","author":"Mayfield","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2017.06.012_bib70","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00277-016-2617-y","article-title":"Tyrosine kinase inhibitors in Ph+ acute lymphoblastic leukaemia: facts and perspectives","volume":"95","author":"Malagola","year":"2016","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.ejca.2017.06.012_bib71","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: children's Oncology Group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.ejca.2017.06.012_bib72","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.ejca.2017.06.012_bib73","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study","volume":"16","author":"Jabbour","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2017.06.012_bib74","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","article-title":"Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL","volume":"128","author":"Rousselot","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejca.2017.06.012_bib75","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/leu.2012.324","article-title":"Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"27","author":"Ottmann","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.ejca.2017.06.012_bib76","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/leu.2014.256","article-title":"Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment","volume":"29","author":"Yeung","year":"2015","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.ejca.2017.06.012_bib77","first-page":"1423","article-title":"Identifying drug-resistant mutations in Ebf1-Pdgfrb Ph-like acute lymphoblastic leukemia","volume":"126","author":"Tran","year":"2015","journal-title":"Annu Meet Abstr Blood"},{"issue":"22","key":"10.1016\/j.ejca.2017.06.012_bib78","first-page":"3957","article-title":"In\u00a0vitro modeling of Ph-like ALL fusions identifies novel kinase-domain mutations as mode of TKI-resistance - implications for targeted therapy","volume":"128","author":"Asari","year":"2016","journal-title":"Annu Meet Abstr Blood"},{"issue":"22","key":"10.1016\/j.ejca.2017.06.012_bib79","first-page":"751","article-title":"GNB1 K89M drives TKI resistance in ETV6-ABL1-positive leukemia","volume":"128","author":"Zimmermannova","year":"2016","journal-title":"Annu Meet Abstr Blood"},{"issue":"1","key":"10.1016\/j.ejca.2017.06.012_bib80","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nm.3751","article-title":"Mutations in G protein beta subunits promote transformation and kinase inhibitor resistance","volume":"21","author":"Yoda","year":"2015","journal-title":"Nat Med"},{"issue":"7347","key":"10.1016\/j.ejca.2017.06.012_bib81","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature09883","article-title":"BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition","volume":"473","author":"Duy","year":"2011","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ejca.2017.06.012_bib82","doi-asserted-by":"crossref","first-page":"e83510","DOI":"10.1371\/journal.pone.0083510","article-title":"Inhibition of PI3K\/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2","volume":"8","author":"Ding","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.ejca.2017.06.012_bib83","doi-asserted-by":"crossref","first-page":"e80070","DOI":"10.1371\/journal.pone.0080070","article-title":"Differential effects of selective inhibitors targeting the PI3K\/AKT\/mTOR pathway in acute lymphoblastic leukemia","volume":"8","author":"Badura","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ejca.2017.06.012_bib84","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.18632\/oncotarget.2842","article-title":"Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model","volume":"6","author":"Hasan","year":"2015","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.ejca.2017.06.012_bib85","first-page":"4087","article-title":"RAS pathway mutations as predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"128","author":"Jerchel","year":"2016","journal-title":"Annu Meet Abstr Blood"},{"issue":"9","key":"10.1016\/j.ejca.2017.06.012_bib86","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/leu.2014.80","article-title":"EMP1, a novel poor prognostic factor in pediatric leukemia regulates prednisolone resistance, cell proliferation, migration and adhesion","volume":"28","author":"Aries","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.ejca.2017.06.012_bib87","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ccell.2015.06.005","article-title":"Activity of the type II JAK2 inhibitor CHZ868 in B Cell acute lymphoblastic leukemia","volume":"28","author":"Wu","year":"2015","journal-title":"Cancer Cell"},{"issue":"22","key":"10.1016\/j.ejca.2017.06.012_bib88","first-page":"2914","article-title":"The frequency and outcome of Ph-like ALL associated abnormalities in childhood acute lymphoblastic leukemia treated on MRC UKALL2003","volume":"128","author":"Schwab","year":"2016","journal-title":"Annu Meet Abstr Blood"},{"issue":"5","key":"10.1016\/j.ejca.2017.06.012_bib89","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11912-017-0589-2","article-title":"Philadelphia-like acute lymphoblastic Leukemia in adults","volume":"19","author":"Herold","year":"2017","journal-title":"Curr Oncol Rep"},{"issue":"23","key":"10.1016\/j.ejca.2017.06.012_bib90","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMc1412123","article-title":"Ph-like acute lymphoblastic leukemia in older adults","volume":"371","author":"Herold","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2017.06.012_bib91","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/ajcp\/aqx005","article-title":"CRLF2-positive B-Cell acute lymphoblastic leukemia in adult patients: a single-institution experience","volume":"147","author":"Konoplev","year":"2017","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.ejca.2017.06.012_bib92","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-017-0431-1","article-title":"Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia","volume":"10","author":"Feng","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2017.06.012_bib93","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood-2009-08-235408","article-title":"Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group","volume":"115","author":"Hertzberg","year":"2010","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.ejca.2017.06.012_bib94","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejca.2017.06.012_bib95","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jmoldx.2016.02.003","article-title":"Validation and implementation of a custom next-generation sequencing clinical assay for hematologic malignancies","volume":"18","author":"Kluk","year":"2016","journal-title":"J Mol Diagn"},{"issue":"23","key":"10.1016\/j.ejca.2017.06.012_bib96","first-page":"2609","article-title":"Rapid capture targeted next generation sequencing (NGS) for detection of genomic kinase- and cytokine receptor rearrangements in B-precursor acute lymphoblastic leukemia","volume":"126","author":"Escherich","year":"2015","journal-title":"Annu Meet Abstr Blood"},{"issue":"23","key":"10.1016\/j.ejca.2017.06.012_bib97","first-page":"696","article-title":"Targeted locus amplification & next generation sequencing for the detection of recurrent and novel gene fusions for improved treatment decisions in pediatric acute lymphoblastic leukemia","volume":"126","author":"Kuiper","year":"2015","journal-title":"Annu Meet Abstr Blood"},{"issue":"6","key":"10.1016\/j.ejca.2017.06.012_bib98","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1200\/JCO.2016.69.6278","article-title":"Use of minimal residual disease assessment to redefine induction failure in pediatric acute lymphoblastic leukemia","volume":"35","author":"O'Connor","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.06.012_bib99","doi-asserted-by":"crossref","first-page":"11790","DOI":"10.1038\/ncomms11790","article-title":"Identification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia","volume":"7","author":"Lilljebjorn","year":"2016","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.ejca.2017.06.012_bib100","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/ng.3535","article-title":"Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults","volume":"48","author":"Yasuda","year":"2016","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.ejca.2017.06.012_bib101","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/ng.3691","article-title":"Deregulation of DUX4 and ERG in acute lymphoblastic leukemia","volume":"48","author":"Zhang","year":"2016","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.ejca.2017.06.012_bib102","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","article-title":"CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins","volume":"90","author":"Carroll","year":"1997","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejca.2017.06.012_bib103","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2141.2010.08323.x","article-title":"A doctor(s) dilemma: ETV6-ABL1 positive acute lymphoblastic leukaemia","volume":"151","author":"Malone","year":"2010","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.ejca.2017.06.012_bib104","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/leu.2008.242","article-title":"Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases","volume":"22","author":"De Keersmaecker","year":"2008","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.ejca.2017.06.012_bib105","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.3324\/haematol.2015.136499","article-title":"NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors","volume":"101","author":"Duployez","year":"2016","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.ejca.2017.06.012_bib106","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.3324\/haematol.2015.139568","article-title":"Imatinib-induced long-term remission in a relapsed RCSD1-ABL1-positive acute lymphoblastic leukemia","volume":"101","author":"Perwein","year":"2016","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.ejca.2017.06.012_bib107","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3324\/haematol.2009.008094","article-title":"A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34)","volume":"94","author":"Mustjoki","year":"2009","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.ejca.2017.06.012_bib108","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.exphem.2015.11.009","article-title":"Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells","volume":"44","author":"Ishibashi","year":"2016","journal-title":"Exp Hematol"},{"issue":"6","key":"10.1016\/j.ejca.2017.06.012_bib109","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/pbc.25327","article-title":"TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP\/PDGFRB translocation","volume":"62","author":"Kobayashi","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2017.06.012_bib110","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/leu.2013.324","article-title":"RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D\/CSF1R fusion responsive to imatinib","volume":"28","author":"Lilljebjorn","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ejca.2017.06.012_bib111","doi-asserted-by":"crossref","first-page":"e32451","DOI":"10.1371\/journal.pone.0032451","article-title":"Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase","volume":"7","author":"Cuesta-Dominguez","year":"2012","journal-title":"PLoS One"},{"issue":"22","key":"10.1016\/j.ejca.2017.06.012_bib112","first-page":"2913","article-title":"A versatile DNA\/RNA NGS targeted capture strategy for detection of fusion genes in pediatric ALL","volume":"128","author":"Fazio","year":"2016","journal-title":"Annu Meet Abstr Blood"},{"issue":"7","key":"10.1016\/j.ejca.2017.06.012_bib113","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/pbc.25975","article-title":"Rapid capture next-generation sequencing in clinical diagnostics of kinase pathway Aberrations in B-Cell precursor ALL","volume":"63","author":"Stadt","year":"2016","journal-title":"Pediatr Blood Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917310535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917310535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T02:30:55Z","timestamp":1602469855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917310535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":113,"alternative-id":["S0959804917310535"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.06.012","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BCR-ABL1-like acute lymphoblastic leukaemia: From bench to bedside","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}